Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$133.08 USD

133.08
1,070,906

-0.38 (-0.28%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $133.07 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SRPT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

6 items in cart

View Cart/Checkout

Sarepta Therapeutics, Inc. [SRPT]

Reports for Purchase

Showing records 601 - 620 ( 672 total )

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 601

03/10/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 10

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 602

03/03/2014

Company Report

Pages: 10

Q4:13 Update - Follow-on Exons in Clinic by Year End - Product Supply Good to Go - FDA Progress Slow, but Suggestive of Potential New Trial Designs

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 603

02/23/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 604

01/17/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 605

01/03/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 606

01/03/2014

Daily Note

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 607

12/13/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 16

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 608

12/08/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 609

12/08/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 610

12/02/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 611

12/02/2013

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 612

11/24/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 25

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 613

11/22/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 614

11/15/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 18

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 615

11/12/2013

Company Report

Pages: 9

Q3 Update - Lowering Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 616

10/17/2013

Daily Note

Pages: 6

Duchenne Community Update Call with Sarepta - H1:14 NDA On-Track - No Manufacturing Update but Future Plans Imply Progress has Been Made

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 617

10/11/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct. 14

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 618

10/03/2013

Industry Report

Pages: 7

Biotechnology/Biopharmaceuticals/BioDefense - WMS Day 1 and KOL Dinner with Dr. McDonald and Friends - The Path Forward in DMD

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 619

09/30/2013

Industry Report

Pages: 14

Biotechnology/Biopharmaceuticals/BioDefense - KOL Dinner with Dr. Craig McDonald, Oct 2 - Looking Ahead to World Muscle

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 50.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 620

09/27/2013

Daily Note

Pages: 5

Key Takeaways - DIA/FDA Oligonucleotide-base Therapeutics Conference

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 10.00

Research Provided by a Third Party
// eof